ReviewThe Lancet. Digital health2020
Artificial intelligence in COVID-19 drug repurposing.
Review in The Lancet. Digital health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.Molecular systems biology · 2021Pooled it
- Artificial Intelligence Applications for COVID-19 in Intensive Care and Emergency Settings: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Niclosamide suppresses breast cancer progression and enhances paclitaxel sensitivity by targeting the ATP6AP1-YY1-XIAP axis.Acta pharmacologica Sinica · 2026Article
- Integrating Artificial Intelligence with Emerging Pharmaceutical Technologies: Current Progress, Clinical Translation, and Future Challenges.International journal of molecular sciences · 2026Review
- DrugDL: dual-modal deep learning framework for multi-property drug prediction and targeted therapy discovery.Bioinformatics (Oxford, England) · 2026Article
- Artificial intelligence at the frontlines: Emerging infectious and parasitic diseases in the digital era.New microbes and new infections · 2026Article
- A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.medRxiv : the preprint server for health sciences · 2026Article
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
- Artificial intelligence drives the identification and screening of novel antibiotics and antimicrobial peptides.Briefings in bioinformatics · 2026Review
- CellAwareGNN: Single-Cell Enhanced Knowledge Graph Foundation Model for Drug Indication Prediction.bioRxiv : the preprint server for biology · 2026Article
- Applications of AI/ML in accelerating the development of pulmonary drug delivery system.Acta pharmaceutica Sinica. B · 2026Review
- Recent applications of artificial intelligence in cancer radiotherapy and immunotherapy: current status and future directions.Frontiers in immunology · 2026Review
- Artificial Intelligence to Guide Repurposing of Drugs.Annual review of medicine · 2026Review
- Opening the black box: insights into ubiquitin-mediated control of innate antiviral immunity and AI-enhanced therapeutics.Frontiers in immunology · 2026Review
- Article
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- Biologically Informed Machine Learning Prioritizes Dietary Supplements That Protect Neural Crest Cells from Ethanol-Induced Epigenetic Dysregulation and Developmental Impairment.International journal of molecular sciences · 2025Article
- How Will AI Shape the Future of Pandemic Response? Early Clues From Data Analytics.Risk analysis : an official publication of the Society for Risk Analysis · 2025Review
- A comprehensive guide to digital neurology. An update on current development on digital neurology derived from the Digital Neuro Hub project.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development.Journal of medicinal chemistry · 2025Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.